Lenalidomide targets the E3 ubiquitin ligase component cereblon that modulates the interferon regulatory factor 4 and down-regulates the NF-κB pathway in ABC-DLBCL (Fig. 4) [328]. This evidence concerns the gene NFKB1 and aneurysmal bone cyst.